Last reviewed 2026-06-02 · How we verify

Pivaloylampicillin (PIVAMPICILLIN)

Phase 2 active Small molecule Under review Quality 0/100

Pivaloylampicillin (generic name: PIVAMPICILLIN) is a pivampicillin drug. It is currently in Phase 2 development.

Pivampicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to the death of the bacterial cell.

Pivaloylaminopenicillin, also known as Pivaloylampicillin, is a small molecule inhibitor of bacterial penicillin-binding protein. It works by inhibiting the bacterial penicillin-binding protein, which is a key target in bacterial cell wall synthesis.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PIVAMPICILLIN
Drug class	pivampicillin
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine the bacterial cell wall as a brick wall. Pivampicillin blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse. This prevents the bacteria from growing and multiplying, ultimately leading to the death of the bacterial cell.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pivaloylampicillin CI brief — competitive landscape report
Pivaloylampicillin updates RSS · CI watch RSS

Frequently asked questions about Pivaloylampicillin

What is Pivaloylampicillin?

Pivaloylampicillin (PIVAMPICILLIN) is a pivampicillin drug.

How does Pivaloylampicillin work?

Pivampicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to the death of the bacterial cell.

What is the generic name of Pivaloylampicillin?

PIVAMPICILLIN is the generic (nonproprietary) name of Pivaloylampicillin.

What drug class is Pivaloylampicillin in?

Pivaloylampicillin belongs to the pivampicillin class. See all pivampicillin drugs at /class/pivampicillin.

What development phase is Pivaloylampicillin in?

Pivaloylampicillin is in Phase 2.

Drug class: All pivampicillin drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing